AR026022A1 - METHOD FOR THE TREATMENT OF OBESITY - Google Patents
METHOD FOR THE TREATMENT OF OBESITYInfo
- Publication number
- AR026022A1 AR026022A1 ARP000105369A ARP000105369A AR026022A1 AR 026022 A1 AR026022 A1 AR 026022A1 AR P000105369 A ARP000105369 A AR P000105369A AR P000105369 A ARP000105369 A AR P000105369A AR 026022 A1 AR026022 A1 AR 026022A1
- Authority
- AR
- Argentina
- Prior art keywords
- obesity
- treatment
- solvatofarma
- animal
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Método para el tratamiento de la obesidad que comprende administrar a un animal que necesite del mismo, un compuesto de formula (1) o una sal o solvatofarmacéuticamente aceptable del mismo. Los métodos para la supresion del apetito, para causarpérdi da de peso, para prevenir el aumento de peso, para afectarpreferencialmente la composicion grasa del cuerpo, para inhibir el antojo del alimento, o para mantener el peso bajo también se describen.Method for the treatment of obesity which comprises administering to an animal in need thereof, a compound of formula (1) or a pharmaceutically acceptable salt or solvatofarma thereof. Methods for appetite suppression, to cause weight loss, to prevent weight gain, to preferentially affect the body's fat composition, to inhibit food cravings, or to keep weight low are also described.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9924275.2A GB9924275D0 (en) | 1999-10-13 | 1999-10-13 | Method for the treatment of obesity |
GB0001861A GB0001861D0 (en) | 2000-01-28 | 2000-01-28 | Method for the treatment of obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
AR026022A1 true AR026022A1 (en) | 2002-12-26 |
Family
ID=26243494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000105369A AR026022A1 (en) | 1999-10-13 | 2000-10-12 | METHOD FOR THE TREATMENT OF OBESITY |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1220673A2 (en) |
JP (1) | JP2003511410A (en) |
AR (1) | AR026022A1 (en) |
AU (1) | AU7750100A (en) |
PE (1) | PE20010744A1 (en) |
WO (1) | WO2001026641A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04001165A (en) | 2001-08-08 | 2004-05-20 | R Orton Kevin | Apparatus and method for electrically conductive weight reduction. |
EP3173082A1 (en) * | 2002-05-17 | 2017-05-31 | Duke University | Method for treating obesity |
SI2316456T1 (en) | 2003-04-29 | 2017-10-30 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss comprising an opioid antagonist and bupropion |
CN101370488B (en) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | Compositions for increasing insulin sensitivity |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
KR20090090316A (en) | 2006-11-09 | 2009-08-25 | 오렉시젠 세러퓨틱스 인크. | Unit dosage package and methods for administering weight loss medications |
CN102026976A (en) * | 2007-12-05 | 2011-04-20 | 阿斯利康(瑞典)有限公司 | Morpholine derivates as antiobesity agents |
JP2011521973A (en) | 2008-05-30 | 2011-07-28 | オレキシジェン・セラピューティクス・インコーポレーテッド | Methods for treating visceral fat conditions |
WO2009147219A1 (en) * | 2008-06-04 | 2009-12-10 | Biovitrum Ab (Publ) | New compounds vii |
BR112012016783A2 (en) | 2010-01-11 | 2015-09-01 | Orexigen Therapeutics Inc | "Uses of the naltrexone compound or pharmaceutically acceptable salt thereof to bupropion or pharmaceutically acceptable salt thereof or composition thereof and methods for providing therapy" |
AU2013271622B2 (en) | 2012-06-06 | 2018-03-01 | Nalpropion Pharmaceuticals Llc | Methods of treating overweight and obesity |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8924528D0 (en) * | 1989-10-31 | 1989-12-20 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
AU744261B2 (en) * | 1997-04-24 | 2002-02-21 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating eating disorders |
AU1403899A (en) * | 1997-11-14 | 1999-06-07 | Glaxo Group Limited | Method of treating addiction to nicotine products |
HUP0100900A3 (en) * | 1998-01-21 | 2002-08-28 | Glaxo Group Ltd | Pharmaceutically active morpholinol and medicaments containing them |
MA26693A1 (en) * | 1998-09-28 | 2004-12-20 | Glaxo Group Ltd | COMPOSITIONS FOR ORAL ADMINISTRATION |
-
2000
- 2000-10-03 WO PCT/US2000/027252 patent/WO2001026641A2/en not_active Application Discontinuation
- 2000-10-03 JP JP2001529431A patent/JP2003511410A/en active Pending
- 2000-10-03 AU AU77501/00A patent/AU7750100A/en not_active Abandoned
- 2000-10-03 EP EP00967281A patent/EP1220673A2/en not_active Withdrawn
- 2000-10-11 PE PE2000001089A patent/PE20010744A1/en not_active Application Discontinuation
- 2000-10-12 AR ARP000105369A patent/AR026022A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PE20010744A1 (en) | 2001-07-23 |
EP1220673A2 (en) | 2002-07-10 |
AU7750100A (en) | 2001-04-23 |
WO2001026641A3 (en) | 2002-01-10 |
JP2003511410A (en) | 2003-03-25 |
WO2001026641A2 (en) | 2001-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR030933A1 (en) | TRIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
CO6331425A2 (en) | COMPOSITIONS THAT INCLUDE N- (3,4-DIFLUORO-2- (2-FLUORO-4-IODOFENILAMINO) 6-METOXIFENIL) -1- (2,3-DIHYDROXIPROXIPROPIL) CICLOPROPAN-1-SULFAMIDA | |
DOP2004001052A (en) | 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1 INHIBITORS AMINO | |
CY1106634T1 (en) | THERAPEUTIC DERIVATIVES OF PIPERAZINE | |
CO5251429A1 (en) | DERIVATIVES OF TER-BUTIL- (7-METHYL-IMIDAZO (1,2-A) PIRIDIN-3- IL) -AMINE PROCEDURE FOR PREPARATION, DRUGS THAT CONTAIN THEM, ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE INHIBITION OF NON-SYNTHEASE AND PHARMACEUTICAL COMPOSITIONS THAT L | |
PA8591701A1 (en) | PIRROLOPIRIMIDINE DERIVATIVES | |
CY1109242T1 (en) | THERAPEUTIC AGENTS USEFUL FOR PAIN TREATMENT | |
AR026022A1 (en) | METHOD FOR THE TREATMENT OF OBESITY | |
UY26635A1 (en) | SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
TR200102646T2 (en) | Treating eating disorders. | |
ES2295609T3 (en) | TIADIAZOLILPIPERAZINA DERIVATIVES USEFUL TO TREAT OR PREVENT A PAIN. | |
CY1111951T1 (en) | PAINYL-CARBOXAMID COMPOUNDS USEFUL FOR PANTS | |
BR0314943A (en) | Cystic Fibrosis Transmembrane Conductance Regulatory Protein Inhibitors and Uses of These | |
CO5200778A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A THERAPEUTICALLY EFFECTIVE AMOUNT OF B ENZIMIDAZOL, ADMINISTERED TO PREVENT AND TREAT CANCER AND INHIBIT METASTASIS | |
AR039190A1 (en) | BENZOFURAN DERIVATIVES, PHARMACEUTICAL COMPOSITION AND MEDICINAL PRODUCT UNDERSTANDING THE COMPOUND | |
TR200101633T2 (en) | Pharmaceutical composition | |
CL2023000196A1 (en) | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of use thereof | |
RU2019121690A (en) | DEXMEDETOMIDINE OR METHOMIDINE FOR USE FOR THE TREATMENT OF SEPARATION ANXIETY IN DOGS | |
AR014964A1 (en) | DERIVATIVES OF INDOL, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AGENTS TO REDUCE INTRAOCULAR PRESSURE, TREAT GLAUCOMA AND OCULAR HYPERTENSION, USE THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR MANUFACTURING OF THESE COMPOSITIONS | |
AU2002357191A1 (en) | Derivatives of isoindigo, indigo and indirubin and use in treating cancer | |
BR0305708A (en) | Benzimidazole derivatives for the treatment of sexual dysfunction | |
ATE366107T1 (en) | USE OF SULFODEHYDROABIETIC ACID TO TREAT INFLAMMATORY BOWEL DISEASE | |
EA200601249A1 (en) | PIPERASINS, SUITABLE FOR THE TREATMENT OF PAIN | |
RU94045271A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for terner's syndrome inhibition | |
NO912414L (en) | RELATIONSHIP WITH MAGIC ACID INHIBITING EFFECT AND PROCEDURE FOR ITS MANUFACTURING. |